Medical News

FDA Application Is Submitted for Evaluating HIV Treatment

January 13, 2004

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Gilead Sciences Inc. has submitted an investigational new-drug application to the Food and Drug Administration to evaluate GS 9005, a potential protease inhibitor therapy that could be taken once daily. The drug's creator said GS 9005 might have a resistance profile that is distinct from commercially available drugs in the protease inhibitor class. Gilead plans to test the drug in healthy volunteers as well as HIV-positive patients. As an experimental drug, GS 9005 has not been determined to be safe or effective in humans for its intended use, Gilead said.

Back to other news for January 13, 2004

Adapted from:
Wall Street Journal

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.